GLP-1 Update July ‘26: Cost-Containment & Clinically-Informed Care

Everywhere you turn, there’s news about GLP-1s: soaring costs, rising demand, and new approved indications and drugs coming to market. It’s enough to make any benefit leader’s head spin. Prioritizing member outcomes and plan sustainability requires being armed with the truth; not just press buzz.

Join Obesity Medicine Association member, Elena Sullivan, PA-C, for a look into what’s changed with the GLP-1 market in the last year, what’s coming, and how you can leverage clinical insights to make responsible decisions for your plan’s long-term sustainability.

In this episode, we’ll explore:

• What new GLP-1 drugs have come to market, and what’s in the pipeline

• The science behind treating obesity as a chronic disease state

• How establishing the right benefits partnerships are crucial for clinically-informed coverage